Abivax Plans Fundraising Post-Junior Trial Data; Cash Reserves at €530M

Abivax is set to raise funds after the release of key trial data in June and is not rushing to secure a partnership or sale. The company reported cash reserves of €530 million ($613 million) as of the end of 2025. It plans to apply for FDA approval for its drug obefazimod by Q4 2023, contingent on positive trial results. Research and development expenses grew by €31.2 million to €177.8 million in 2025, indicating increased spending ahead as it prepares for a commercial launch.